^○Yasushi Goto¹, Benjamin J. Solomon², Geoffrey Liu³, Enriqueta Felip⁴, Tony S. K. Mok⁵, Ross A. Soo⁶, Julien Mazieres⁷, Alice T. Shaw⁸, Filippo de Marinis⁹, Yi-Long Wu¹⁰, Dong-Wan Kim¹¹, Jean-Francois Martini¹², Rossella Messina¹³, Jolanda Paolini¹³, Anna Polli¹³, Despina Thomaidou¹⁴, Francesca Toffalorio¹³, Todd M. Bauer¹⁵ (1.National Cancer Center Hospital, Tokyo, Japan, 2.Peter MacCallum Cancer Centre, Melbourne, VIC, Australia, 3.Princess Margaret Cancer Centre, Toronto, ON, Canada, 4.Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain, 5.State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, 6.National University Cancer Institute, Singapore, 7.Toulouse University Hospital and Centre de Recherche Cancérologie Toulouse CRCT, INSERM, France, 8.Massachusetts General Hospital Cancer Center, Boston, MA, USA, 9.European Institute of Oncology, IRCCS, Milan, Italy, 10.Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangdong, China, 11.Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea, 12.Pfizer, La Jolla, CA, USA, 13.Pfizer, Milan, Italy, 14.Pfizer, Athens, Greece, 15.Greco-Hainsworth Centers for Research/Tennessee Oncology, Nashville, TN, USA)

^○坂口 裕之¹, 西山 明宏¹, 松本 桂², 田嶋 敦², 宮城 栄重³, 遠山 直志³, 古垣 耕⁴, 松本 満里恵⁵, 片山 量平⁵, 竹内 伸司¹ (1.金沢大学附属病院腫瘍内科, 2.金沢大学革新ゲノム情報学, 3.金沢大学附属病院先端医療開発センター, 4.中外製薬株式会社, 5.がん研究会がん化学療法センター基礎研究部)

^○三角 明里¹, 葉 清隆¹, 大江 裕一郎², 服部 剛弘³, 小谷 昌広⁴, 近森 研一⁵, 横尾 慶紀⁶, 善家 義貴¹, 泉 大樹¹, 酒井 徹也¹, 梅村 茂樹¹, 杉山 栄里¹, 宇田川 響¹, 田中 悠¹, 加藤 祐樹¹, 平田 剛士¹, 松本 慎吾¹, 後藤 功一¹ (1.国立がん研究センター東病院呼吸器内科, 2.国立がん研究センター中央病院, 3.兵庫県立がんセンター, 4.鳥取大学医学部附属病院, 5.山口宇部医療センター, 6.手稲渓仁会病院)

^○Yuichiro Ohe¹, Noriko Yanagitani², Shunichi Sugawara³, Hidetoshi Hayashi⁴, Yutaka Fujiwara⁵, Koichi Goto⁶, Toshiaki Takahashi⁷, Ryo Toyozawa⁸, Xianyu Zhang⁹, Shuanglian Li⁹, Rose K. Lai⁹, Nathan A. Pennell¹⁰, Maurice Perol¹¹, Lyudmila Bazhenova¹², Takashi Seto⁸ (1.National Cancer Center Hospital, Tokyo, Japan, 2.The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, 3.Sendai Kosei Hospital, Sendai, Japan, 4.Kindai University Hospital, Osaka, Japan, 5.Aichi Cancer Center Hospital, Nagoya, Japan, 6.National Cancer Center Hospital East, Kashiwa, Japan, 7.Shizuoka Cancer Center, Shizuoka, Japan, 8.National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 9.Nuvation Bio, New York, NY, USA, 10.Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA, 11.Léon Bérard Cancer Center, Lyon, France, 12.University of California San Diego Moores Cancer Center, San Diego, CA, USA)

^○Noboru Yamamoto¹, Minal Barve², Frans Opdam³, Hai-Yan Tu⁴, Yi-Long Wu⁴, David Berz⁵, Lukas Schroeter⁶, Maren Rohrbacher⁷, Behbood Sadrolhefazi⁸, John V Heymach⁹, Kiyotaka Yoh¹⁰ (1.Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, 2.Mary Crowley Cancer Research, Dallas, TX, USA, 3.Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands, 4.Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China, 5.Valkyrie Clinical Trials, Inc., Los Angeles, CA, USA, 6.Boehringer Ingelheim Pharma GmbH ＆ Co. KG, Biberach an der Riss, Germany, 7.Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 8.Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 9.Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 10.Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan)

^○後藤 功一¹, 西野 和美², 榊原 純³, 岡本 勇⁴, Shun Lu⁵ (1.国立がん研究センター東病院, 2.大阪国際がんセンター, 3.北海道大学病院, 4.九州大学病院, 5.Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China)